Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Danielle Stewart

Physician Assistant, Surgical Gilbert, AZ Physician Assistant

NPI 1073110722 CMS profile 10703053

2940 E Banner Gateway Dr Ste 200-250, Gilbert, AZ 85234

Open in the dashboard

General payments

$2,278

140 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Danielle Stewart of Gilbert, AZ is reported in the CMS Open Payments database as having received $2,278 across 140 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Physician Assistant, Surgical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $209 26
2023 General $207 4
2022 General $927 50
2021 General $935 60

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Danielle Stewart
  • Physician Assistant, Surgical median
  • Middle half of Physician Assistant, Surgical
  • National median

In program year 2025, general payments to Danielle Stewart were reported at $209. Among 8,152 Physician Assistant, Surgical profiles paid that year, the median was $146 and the middle half received between $51 and $385.

Show as a table
Year Danielle Stewart Physician Assistant, Surgical median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $935 $111 $36–$285 $132
2022 $927 $126 $44–$350 $149
2023 $207 $137 $47–$355 $160
2024 $0 $146 $49–$384 $164
2025 $209 $146 $51–$385 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $970 64 payments
  2. Orthofix Medical, Inc. $172 25 payments
  3. Sunovion Pharmaceuticals Inc. $151 6 payments
  4. Stryker Corporation $143 1 payment
  5. Paragon 28, Inc. $118 1 payment
  6. Novartis Pharmaceuticals Corporation $95 4 payments
  7. Lilly USA, LLC $90 6 payments
  8. Amgen Inc. $78 4 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $72 5 payments
  10. Amarin Pharma Inc. $54 4 payments
  11. Other $335 20 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,278 140 payments
Products named General payments · program years 2021–2025
  1. UBRELVY $521 30 payments
  2. VRAYLAR $242 19 payments
  3. QULIPTA $193 14 payments
  4. Physio-Stim $172 25 payments
  5. GEMTESA $151 6 payments
  6. PROPHECY $143 1 payment
  7. INFINITY $143 1 payment
  8. MONKEY RINGS $118 1 payment
  9. Kerendia $72 5 payments
  10. TRULICITY $58 4 payments
  11. Other $928 52 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

123

Median for Physician Assistant: 241

Drug cost

$679

Median for Physician Assistant: $4,110

Branded share of claims

0%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone Hcl Generic 69 $305
Gabapentin Generic 37 $268
Cefadroxil Generic 17 $106

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$17,687

Of which drugs: $311

Medicare patients

148

Average age 74

Services billed

1,323

99 women, 49 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 72%
High blood pressure 67%
Ischemic heart disease 22%
Chronic kidney disease 22%
Diabetes 21%
Depression 21%
Osteoporosis 17%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 12 880 $86

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

140 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record